1832 Asset Management’s BioNTech BNTX Stock Holding History

1832 Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100	Closed	-$8.04K	–	701
2024 Q2	$8.04K	Hold	100	–	–	﹤0.01%	787
2024 Q1	$9.22K	Hold	100	–	–	﹤0.01%	772
2023 Q4	$10.6K	Hold	100	–	–	﹤0.01%	747
2023 Q3	$10.9K	Hold	100	–	–	﹤0.01%	750
2023 Q2	$10.8K	Hold	100	–	–	﹤0.01%	753
2023 Q1	$12.5K	Hold	100	–	–	﹤0.01%	784
2022 Q4	$15K	Hold	100	–	–	﹤0.01%	805
2022 Q3	$13K	Hold	100	–	–	﹤0.01%	787
2022 Q2	$15K	Hold	100	–	–	﹤0.01%	792
2022 Q1	$17K	Hold	100	–	–	﹤0.01%	845
2021 Q4	$23K	Hold	100	–	–	﹤0.01%	620
2021 Q3	$27K	Buy	+100	New	+$31.8K	﹤0.01%	775
2021 Q2	–	Sell	-367,600	Closed	-$38.6M	–	730
2021 Q1	$38.6M	Buy	+367,600	New	+$39M	0.08%	192

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1832 Asset Management's BNTX Position: Q3 2024 in Review

1832 Asset Management sold out of BioNTech (BNTX) in Q3 2024, closing a stake of 100 shares — an estimated $8.04K sold.

1832 Asset Management first reported a position in BNTX in Q1 2021 and held it in 13 quarters. The position peaked at $38.6M in Q1 2021. 296 funds tracked by Wall St. Rank hold BNTX as of Q3 2024.

1832 Asset Management reported no remaining BioNTech position as of Q3 2024 after selling out during the quarter.
1832 Asset Management sold 100 BioNTech shares in Q3 2024, an estimated $8.04K.
1832 Asset Management first reported a position in BioNTech in Q1 2021 and held it in 13 quarters.
1832 Asset Management's BioNTech position peaked at $38.6M in Q1 2021.
296 funds tracked by Wall St. Rank held BioNTech as of Q3 2024.

Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.